CD274 and neoplasm: Despite the fact that current guidelines do not routinely recommend PET/CT for follow-up of any of the mentioned thoracic tumor entities [49,50,51], evidence on the utility of PET/CT in assessing response to ICI therapies, especially for NSCLC, is evolving: Tumor SUVmax has been excluded as a significant predictor of survival in different analyses [10,56,57], but it correlates with PD-L1 status [10,58,59], and thus also with response to ICI therapies [60].